Literature DB >> 3084428

Cytogenetic effects of etoposide (VP-16) on human lymphocytes; with special reference to the relation between sister chromatid exchange and chromatid breakage.

K Tominaga, T Shinkai, N Saijo, T Nakajima, H Ochi, K Suemasu.   

Abstract

The effects of etoposide (VP-16) on sister chromatid exchange (SCE) and chromosome abnormalities were studied by using human peripheral lymphocytes. This drug produced a significant increase in the SCE frequency and chromosomal aberrations such as breaks, exchanges, and tetraploidy with or without endoreduplication. Analysis of the breakpoints of chromatid deletion with respect to their association with SCE in the metaphases from the second division demonstrated that VP-16-induced deletions arose with little dependence on the site of SCE. It is suggested that chromatid deletions induced by this drug derive from unrepaired chromatid breaks rather than from incomplete exchanges.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3084428

Source DB:  PubMed          Journal:  Jpn J Cancer Res        ISSN: 0910-5050


  4 in total

1.  Possible association of BLM in decreasing DNA double strand breaks during DNA replication.

Authors:  W Wang; M Seki; Y Narita; E Sonoda; S Takeda; K Yamada; T Masuko; T Katada; T Enomoto
Journal:  EMBO J       Date:  2000-07-03       Impact factor: 11.598

2.  Protein binding, sister chromatid exchange and expression of oncogene proteins in patients treated with cisplatinum (cisDDP)-based chemotherapy.

Authors:  F Perera; H K Fischman; K Hemminki; P Brandt-Rauf; H L Niman; S Smith; E Toporoff; K O'Dowd; M X Tang; W Y Tsai
Journal:  Arch Toxicol       Date:  1990       Impact factor: 5.153

Review 3.  Pharmacodynamics and long-term toxicity of etoposide.

Authors:  K Kobayashi; M J Ratain
Journal:  Cancer Chemother Pharmacol       Date:  1994       Impact factor: 3.333

Review 4.  Utility of a next-generation framework for assessment of genomic damage: A case study using the pharmaceutical drug candidate etoposide.

Authors:  John Nicolette; Mirjam Luijten; Jennifer C Sasaki; Laura Custer; Michelle Embry; Roland Froetschl; George Johnson; Gladys Ouedraogo; Raja Settivari; Veronique Thybaud; Kerry L Dearfield
Journal:  Environ Mol Mutagen       Date:  2021-11-22       Impact factor: 3.579

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.